Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2009 2
2010 2
2012 1
2015 1
2017 3
2018 3
2019 3
2020 3
2021 8
2022 6
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism.
Konstantinides SV, Vicaut E, Danays T, Becattini C, Bertoletti L, Beyer-Westendorf J, Bouvaist H, Couturaud F, Dellas C, Duerschmied D, Empen K, Ferrari E, Galiè N, Jiménez D, Kostrubiec M, Kozak M, Kupatt C, Lang IM, Lankeit M, Meneveau N, Palazzini M, Pruszczyk P, Rugolotto M, Salvi A, Sanchez O, Schellong S, Sobkowicz B, Meyer G. Konstantinides SV, et al. Among authors: couturaud f. J Am Coll Cardiol. 2017 Mar 28;69(12):1536-1544. doi: 10.1016/j.jacc.2016.12.039. J Am Coll Cardiol. 2017. PMID: 28335835 Free article. Clinical Trial.
BACKGROUND: The long-term effect of thrombolytic treatment of pulmonary embolism (PE) is unknown. ...RESULTS: Long-term (median 37.8 months) survival was assessed in 353 of 359 (98.3%) patients in the thrombolysis arm and in 343 of 350 (98.0%) in the placebo arm. .. …
BACKGROUND: The long-term effect of thrombolytic treatment of pulmonary embolism (PE) is unknown. ...RESULTS: Long-term (media …
Clinical Presentation and Short- and Long-term Outcomes in Patients With Isolated Distal Deep Vein Thrombosis vs Proximal Deep Vein Thrombosis in the RIETE Registry.
Bikdeli B, Caraballo C, Trujillo-Santos J, Galanaud JP, di Micco P, Rosa V, Cusidó GV, Schellong S, Mellado M, Del Valle Morales M, Gavín-Sebastián O, Mazzolai L, Krumholz HM, Monreal M; RIETE Investigators. Bikdeli B, et al. JAMA Cardiol. 2022 Aug 1;7(8):857-865. doi: 10.1001/jamacardio.2022.1988. JAMA Cardiol. 2022. PMID: 35830171 Free PMC article.
IMPORTANCE: Insufficient data exist about the clinical presentation, short-term, and long-term outcomes of patients with isolated distal deep vein thrombosis (IDDVT), that is, thrombosis in infrapopliteal veins without proximal extension or pulmonary embolism (PE). …
IMPORTANCE: Insufficient data exist about the clinical presentation, short-term, and long-term outcomes of patients with isola …
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
EINSTEIN–PE Investigators; Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. EINSTEIN–PE Investigators, et al. N Engl J Med. 2012 Apr 5;366(14):1287-97. doi: 10.1056/NEJMoa1113572. Epub 2012 Mar 26. N Engl J Med. 2012. PMID: 22449293 Free article. Clinical Trial.
CONCLUSIONS: A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of pulmonary embolism and had a potentially improved benefit-risk profile. ...
CONCLUSIONS: A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of …
Pulmonary Embolism and Chronic Obstructive Pulmonary Disease.
Bertoletti L, Couturaud F, Sanchez O, Jimenez D. Bertoletti L, et al. Among authors: couturaud f. Semin Thromb Hemost. 2023 Nov;49(8):809-815. doi: 10.1055/s-0042-1756190. Epub 2022 Sep 15. Semin Thromb Hemost. 2023. PMID: 36108648 Review.
However, unlike other risk factors such as contraception, the presence of COPD can modify the initial presentation of VTE and worsen the short-term prognosis of patients who have acute pulmonary embolism (PE), particularly during a COPD exacerbation. ...
However, unlike other risk factors such as contraception, the presence of COPD can modify the initial presentation of VTE and worsen the sho …
Diagnosis of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism.
Klok FA, Couturaud F, Delcroix M, Humbert M. Klok FA, et al. Among authors: couturaud f. Eur Respir J. 2020 Jun 25;55(6):2000189. doi: 10.1183/13993003.00189-2020. Print 2020 Jun. Eur Respir J. 2020. PMID: 32184319 Free article. Review.
Chronic thromboembolic pulmonary hypertension (CTEPH) is the most severe long-term complication of acute pulmonary embolism (PE). Untreated CTEPH is fatal, but, if diagnosed in time, successful surgical (pulmonary endarterectomy), medical (pulmonary hypertension drugs) and …
Chronic thromboembolic pulmonary hypertension (CTEPH) is the most severe long-term complication of acute pulmonary embolism (PE). Unt …
Factors predicting outcome after pulmonary endarterectomy.
Tromeur C, Jaïs X, Mercier O, Couturaud F, Montani D, Savale L, Jevnikar M, Weatherald J, Sitbon O, Parent F, Fabre D, Mussot S, Dartevelle P, Humbert M, Simonneau G, Fadel E. Tromeur C, et al. Among authors: couturaud f. PLoS One. 2018 Jun 21;13(6):e0198198. doi: 10.1371/journal.pone.0198198. eCollection 2018. PLoS One. 2018. PMID: 29927944 Free PMC article.
Preoperative cardiac output (CO) and TLCO predicted hemodynamic improvement. CONCLUSION: PEA is associated with an excellent long-term survival and a marked improvement in clinical status and hemodynamics. ...
Preoperative cardiac output (CO) and TLCO predicted hemodynamic improvement. CONCLUSION: PEA is associated with an excellent long-term …
A case of acute pulmonary embolism with severe haemoptysis.
Le Mao R, Tromeur C, Couturaud F. Le Mao R, et al. Among authors: couturaud f. Thromb Res. 2021 Dec;208:199-201. doi: 10.1016/j.thromres.2021.05.011. Epub 2021 May 18. Thromb Res. 2021. PMID: 34045054 Review.
After haemoptysis has been resolved, there is also uncertainty on restarting anticoagulation modalities. Regarding long-term management, the decision to stop at three months or to prolong indefinitely based on international recommendation is also challenging in the case of …
After haemoptysis has been resolved, there is also uncertainty on restarting anticoagulation modalities. Regarding long-term manageme …
Recovery of right ventricular function after intermediate-risk pulmonary embolism: results from the multicentre Pulmonary Embolism International Trial (PEITHO)-2.
Mavromanoli AC, Barco S, Ageno W, Bouvaist H, Brodmann M, Cuccia C, Couturaud F, Dellas C, Dimopoulos K, Duerschmied D, Empen K, Faggiano P, Ferrari E, Galiè N, Galvani M, Ghuysen A, Giannakoulas G, Huisman MV, Jiménez D, Kozak M, Lang IM, Meneveau N, Münzel T, Palazzini M, Petris AO, Piovaccari G, Salvi A, Schellong S, Schmidt KH, Verschuren F, Schmidtmann I, Toenges G, Klok FA, Konstantinides SV; PEITHO-2 Investigators. Mavromanoli AC, et al. Among authors: couturaud f. Clin Res Cardiol. 2023 Oct;112(10):1372-1381. doi: 10.1007/s00392-022-02138-4. Epub 2022 Dec 21. Clin Res Cardiol. 2023. PMID: 36539534 Free PMC article. Clinical Trial.
Almost one in four patients, however, continued to have evidence of RV dysfunction over the long term....
Almost one in four patients, however, continued to have evidence of RV dysfunction over the long term....
[Anticoagulation after an acute pulmonary embolism].
Le Mao R, Tromeur C, Couturaud F. Le Mao R, et al. Among authors: couturaud f. Presse Med. 2017 Jul-Aug;46(7-8 Pt 1):728-738. doi: 10.1016/j.lpm.2017.06.015. Epub 2017 Jul 26. Presse Med. 2017. PMID: 28756076 French.
Three major results are now available: (1) the minimal duration of anticoagulation for pulmonary embolism is 3 months; (2) after pulmonary embolism that was provoked by a major transient risk factor, the risk of recurrence is low and does not justify to prolong anticoagulation be …
Three major results are now available: (1) the minimal duration of anticoagulation for pulmonary embolism is 3 months; (2) after pulmonary e …
Long-Term Risk of Major Bleeding after Discontinuing Anticoagulation for Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis.
Khan F, Rahman A, Tritschler T, Carrier M, Kearon C, Weitz JI, Schulman S, Couturaud F, Becattini C, Agnelli G, Brighton TA, Lensing AWA, Pinede L, Parpia S, Geersing GJ, Takada T, Bradbury CA, Andreozzi GM, Palareti G, Prandoni P, Buller HR, Mallick R, Hutton B, Thavorn K, Le Gal G, Rodger MA, Fergusson DA. Khan F, et al. Among authors: couturaud f. Thromb Haemost. 2022 Jul;122(7):1186-1197. doi: 10.1055/a-1690-8728. Epub 2021 Nov 9. Thromb Haemost. 2022. PMID: 34753191
BACKGROUND: The long-term risk of major bleeding after discontinuing anticoagulant therapy for a first unprovoked venous thromboembolism (VTE) is uncertain. ...
BACKGROUND: The long-term risk of major bleeding after discontinuing anticoagulant therapy for a first unprovoked venous thromboembol …
29 results